Thalassemia and venous thromboembolism

Mediterranean Journal of Hematology and Infectious Diseases

Volumn 3, Issue 1, 2011, Pages

  Succar, Julien ^a   Musallam, Khaled M ^a   Taher, Ali T ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926428640     PISSN: None     EISSN: 20353006     Source Type: Journal    
DOI: 10.4084/MJHID.2011.025     Document Type: Article

References (39)

1. Weatherall DJ, Clegg JB. The thalassaemia syndromes. 4th ed. Oxford; Malden, MA: Blackwell Science; 2001. doi:10.1002/9780470696705
2. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005; 353:1135-1146. doi:10.1056/NEJMra050436 PMid:16162884
3. Sturgeon P, Itano HA, Bergren WR. Genetic and biochemical studies of intermediate types of Cooley's anaemia. Br J Haematol 1955; 1:264-277. doi:10.1111/j.1365-2141.1955.tb05509.x PMid:13240015
4. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis 2006; 37:12-20. doi:10.1016/j.bcmd.2006.04.005 PMid:16737833
5. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010; 115:1886-1892. doi:10.1182/blood-2009-09-243154 PMid:20032507
6. Borgna Pignatti C, Carnelli V, Caruso V, Dore F, De Mattia D, Di Palma A, et al. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol 1998; 99:76-79 doi:10.1159/000040814 PMid:9554453
7. Taher A, Isma'eel H, Mehio G, Bignamini D, Kattamis A, Rachmilewitz EA, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006; 96:488-491. PMid:17003927
8. Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev 2008; 22:283-292. doi:10.1016/j.blre.2008.04.001 PMid:18511163
9. Winichagoon P, Fucharoen S, Wasi P. Increased circulating platelet aggregates in thalassaemia. Southeast Asian J Trop Med Public Health 1981; 12:556-560. PMid:7344105
10. Del Principe D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G. PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassaemic patients. Br J Haematol 1993; 84:111-117. doi:10.1111/j.1365-2141.1993.tb03033.x PMid:7687856
11. Ruf A, Pick M, Deutsch V, Patscheke H, Goldfarb A, Rachmilewitz EA, et al. In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with betathalassaemia major. Br J Haematol 1997; 98:51-56. doi:10.1046/j.1365-2141.1997.1502965.x PMid:9233563
12. Eldor A, Krausz Y, Atlan H, Snyder D, Goldfarb A, Hy-Am E, et al. Platelet survival in patients with beta-thalassemia. Am J Hematol 1989; 32:94-99. doi:10.1002/ajh.2830320204 PMid:2757016
13. Eldor A, Lellouche F, Goldfarb A, Rachmilewitz EA, Maclouf J. In vivo platelet activation in beta-thalassemia major reflected by increased platelet-thromboxane urinary metabolites. Blood 1991; 77:1749-1753. PMid:2015401
14. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. Ann N Y Acad Sci 2005; 1054:317-324. doi:10.1196/annals.1345.039 PMid:16339680
15. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A. In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: a consequence of splenectomy. Int J Hematol 2003; 77:299-303. doi:10.1007/BF02983790 PMid:12731676
16. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Nonspecific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity. Br J Haematol 1978; 40:255-263. doi:10.1111/j.1365-2141.1978.tb03662.x PMid:708645
17. Kuypers FA, de Jong K. The role of phosphatidylserine in recognition and removal of erythrocytes. Cell Mol Biol (Noisyle-grand) 2004; 50:147-158.
18. Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD. Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes. Br J Haematol 2001; 112:48-50. doi:10.1046/j.1365-2141.2001.02482.x PMid:11167782
19. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am J Hematol 1993; 44:63-65. doi:10.1002/ajh.2830440114
20. Helley D, Eldor A, Girot R, Ducrocq R, Guillin MC, Bezeaud A. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia. Thromb Haemost 1996; 76:322-327. PMid:8883264
21. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Onpun S, Chuncharunee S, Thakkinstian A, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/beta-thalassaemic patients. Br J Haematol 2002; 118:893-898. doi:10.1046/j.1365-2141.2002.03711.x PMid:12181063
22. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000; 111:467-473. doi:10.1046/j.1365-2141.2000.02376.x PMid:11122086
23. Chen S, Eldor A, Barshtein G, Zhang S, Goldfarb A, Rachmilewitz E, et al. Enhanced aggregability of red blood cells of beta-thalassemia major patients. Am J Physiol 1996; 270:H1951-1956. PMid:8764243
24. Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A. Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica 2008; 93:941-942. doi:10.3324/haematol.12460 PMid:18460647
25. Butthep P, Bunyaratvej A, Funahara Y, Kitaguchi H, Fucharoen S, Sato S, et al. Alterations in vascular endothelial cell-related plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb Haemost 1995; 74:1045-1049. PMid:8560411
26. Butthep P, Bunyaratvej A, Funahara Y, Kitaguchi H, Fucharoen S, Sato S, et al. Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study. Southeast Asian J Trop Med Public Health 1997; 28 Suppl 3:141-148A. PMid:9640617
27. Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G. Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells. Br J Haematol 1999; 106:178-181. doi:10.1046/j.1365-2141.1999.01489.x PMid:10444184
28. Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am J Hematol 2002; 70:100-106. doi:10.1002/ajh.10101 PMid:12111782
29. Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann N Y Acad Sci 2010; 1202:231-236. doi:10.1111/j.1749-6632.2010.05548.x PMid:20712798
30. Zalloua PA, Shbaklo H, Mourad YA, Koussa S, Taher A. Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb Haemost 2003; 89:767-768. PMid:12669135
31. Iolascon A, Giordano P, Storelli S, Li HH, Coppola B, Piga A, et al. Thrombophilia in thalassemia major patients: analysis of genetic predisposing factors. Haematologica 2001; 86:1112-1113. PMid:11602424
32. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89:1187-1193. PMid:15477202
33. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C, et al. Survival and causes of death in thalassaemia major. Lancet 1989; 2:27-30. doi:10.1016/S0140-6736(89)90264-X
34. Manfre L, Giarratano E, Maggio A, Banco A, Vaccaro G, Lagalla R. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol 1999; 173:1477-1480. PMid:10584785
35. Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 2010; 8:54-59. doi:10.1111/j.1538-7836.2009.03651.x PMid:19817994
36. Taher AT, Musallam KM, El-Beshlawy A, Karimi M, Daar S, Belhoul K, et al. Age-related complications in treatment-naive patients with thalassaemia intermedia. Br J Haematol 2010; 150:486-489. PMid:20456362
37. Taher AT, Musallam KM, Karimi M, El-Beshlawy A, Belhoul K, Daar S, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 2010; 8:2152-2158. doi:10.1111/j.1538-7836.2010.03940.x PMid:20546125
38. Sumiyoshi A, Thakerngpol K, Sonakul D. Pulmonary microthromboemboli in thalassemic cases. Southeast Asian J Trop Med Public Health 1992; 23 Suppl 2:29-31.
39. Tripodi A, Cappellini MD, Chantarangkul V, Padovan L, Fasulo MR, Marcon A, et al. Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in plateletpoor plasma. Haematologica 2009; 94:1520-1527. doi:10.3324/haematol.2009.010546 PMid:19648162 PMCid:2770962